Results 81 to 90 of about 15,140 (255)

A meta-analysis comparing efficacy of continuous terbinafine with intermittent itraconazole for toenail onychomycosis

Indian Journal of Dermatology, 2010
Background: Toenail onychomycosis is a challenge for clinicians to treat. While both Itraconazole and terbinafine have proven to be effective against onychomycosis, very little is known about their comparative efficacy in achieving mycological and ...
Trivedi N, Shah P
doaj  

A Week of Oral Terbinafine Pulse Regimen Every Three Months to Treat all Dermatophyte Onychomycosis

Journal of Fungi, 2019
Terbinafine has proved to treat numerous fungal infections, including onychomycosis, successfully. Due to its liver metabolization and dependency on the cytochrome P450 enzyme complex, undesirable drug interaction are highly probable.
Anarosa B. Sprenger, Katia Sheylla Malta Purim, Flávia Sprenger, Flávio Queiroz-Telles   +3 more
doaj   +1 more source

A Double‐Blind Randomised Clinical Trial of Terbinafine‐Nanostructured Lipid Carriers: Should We Anticipate This Strategy for Effective Topical Treatment of Onychomycosis?

Mycoses, Volume 68, Issue 6, June 2025.
ABSTRACT Background Oral terbinafine (TBF) is the drug of choice for onychomycosis management. To treat and heal the rough and thick nail tissue affected by fungal agents, a high dose and plasma concentration of this drug is necessary. This, however, poses a life‐threatening risk due to the cytotoxic side effects, drug–drug interactions, and adverse ...
Shima Parsay, Majid Saeedi, Mahdi Abastabar, Mohammad Taghi Hedayati, Seyyed Mobin Rahimnia, Nasim Gholizadeh, Armaghan Kazeminejad, Katayoun Morteza‐Semnani, Roozbeh Zare Gashti, Kofi Asare‐Addo, Maryam Moazeni, Ali Nokhodchi   +11 more
wiley   +1 more source

Update on terbinafine with a focus on dermatophytoses

Clinical, Cosmetic and Investigational Dermatology, 2009
Since terbinafine was introduced on the world market 17 years ago, it has become the leading antifungal for the treatment of superficial fungal infections, aided by unique pharmacologic and microbiologic profiles. This article reviews mode of action, antimycotic spectrum and disposition profile of terbinafine.
Susan M. Abdel-Rahman, Jason G. Newland
openaire   +4 more sources

Comparative efficacy of selenoureido carbonic anhydrase inhibitors and azole antifungal drugs against clinical isolates of Malassezia pachydermatis

Veterinary Dermatology, Volume 36, Issue 3, Page 302-313, June 2025.
Background – Malassezia pachydermatis (MP) is implicated in severe dermatitis and otitis externa (OE) of companion animals and recently gained attention for its increasing resistance to azole compounds. For this reason, developing novel therapeutic strategies is of great interest. In a previous work, we used reference yeast isolates to evaluate several
Costanza Spadini, Nicolò Mezzasalma, Amienwanlen Eugene Odigie, Andrea Angeli, Fabrizio Carta, Silvia Selleri, Emanuele Gandolfo, Simone Taddei, Valentina Franceschi, Sergio Minesso, Claudiu T. Supuran, Clotilde Silvia Cabassi   +11 more
wiley   +1 more source

Correlation of In Vitro Susceptibility Based on MICs and Squalene Epoxidase Mutations with Clinical Response to Terbinafine in Patients with Tinea Corporis/Cruris

Antimicrobial Agents and Chemotherapy, 2018
Recalcitrant dermatophytoses are on the rise in India. High MICs of terbinafine (TRB) and squalene epoxidase (SQLE) gene mutations conferring resistance in Trichophyton spp. ABSTRACT Recalcitrant dermatophytoses are on the rise in India.
A. Khurana, Aradhana Masih, A. Chowdhary, K. Sardana, S. Borker, Aastha Gupta, R. Gautam, P. Sharma, D. Jain   +8 more
semanticscholar   +1 more source

Von Zumbusch’s pustular psoriasis associated with oral terbinafine

Journal of Dermatology and Dermatologic Surgery, 2017
Adverse skin reactions have been reported in 2.7% of patients receiving oral terbinafine. Less common but life-threatening reactions include acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson syndrome, toxic epidermal necrolysis ...
Naoufal Hjira, Adil Boudhas, Rachid Frikh, Noureddine Baba, Mohammed Oukabli, Mohammed Boui   +5 more
doaj   +1 more source

Drug Interactions With Tamoxifen and Treatment Effectiveness in Premenopausal Breast Cancer Patients: A Bayesian Joint Modeling Approach

Pharmacoepidemiology and Drug Safety, Volume 34, Issue 5, May 2025.
ABSTRACT Purpose Tamoxifen is guideline treatment for premenopausal women with estrogen receptor‐positive (ER+) breast cancer. Therapeutic efficacy relies partly on tamoxifen biotransformation by CYP2D6, CYP2C19, and CYP3A4 enzymes. We conducted a cohort study to evaluate whether concomitant prescription of drugs that inhibit these enzymes impacted ...
Kirsten M. Woolpert, Deirdre P. Cronin‐Fenton, Per Damkier, Anders Kjærsgaard, Stephen Hamilton‐Dutoit, Bent Ejlertsen, Richard F. MacLehose, Peer Christiansen, Rebecca A. Silliman, Timothy L. Lash, Thomas P. Ahern, Lindsay J. Collin   +11 more
wiley   +1 more source

Frequency and Implications of High‐Risk Pharmacogenomic Phenotypes Identified in a Diverse Australian Pediatric Oncology Cohort

Clinical and Translational Science, Volume 18, Issue 5, May 2025.
ABSTRACT Pharmacogenomics remains underutilized in pediatric oncology, despite the existence of evidence‐based guidelines. Implementation of pharmacogenomics‐informed prescribing could improve medication safety and efficacy in pediatric oncology patients, who are at high risk of adverse drug reactions.
Claire Moore, Andreas Halman, Tayla Stenta, Dhrita Khatri, Elizabeth Williams, Roxanne Dyas, Julian Stolper, David A. Elliott, Rachel Conyers   +8 more
wiley   +1 more source

Terbinafine-induced lichenoid drug eruption: case report and review of terbinafine-associated cutaneous adverse events.

Dermatology Online Journal, 2020
Terbinafine is an antifungal agent used in the treatment of hair, nail, and skin dermatophyte infections. Skin side effects to terbinafine are not common.
Philip R. Cohen, C. Erickson, A. Calame
semanticscholar   +1 more source